Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact.

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM.

Histol Histopathol. 2012 Oct;27(10):1315-25. doi: 10.14670/HH-27.1315.

PMID:
22936450
2.

Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.

De Brot M, Rocha RM, Soares FA, Gobbi H.

Pathology. 2012 Jun;44(4):303-12. doi: 10.1097/PAT.0b013e3283534bcb.

PMID:
22544210
3.

Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness.

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM.

Histopathology. 2012 Sep;61(3):350-64. doi: 10.1111/j.1365-2559.2012.04223.x. Epub 2012 Jun 13.

PMID:
22690749
5.

LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.

Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.

Anticancer Res. 2004 Jul-Aug;24(4):2391-400.

6.

Cyclo-oxygenase-2 (COX-2) mRNA expression and hormone receptor status in breast cancer.

McCarthy K, Bustin SA, Ogunkolade B, Khalaf S, Laban CA, McVittie CJ, Carpenter R, Jenkins PJ.

Eur J Surg Oncol. 2006 Sep;32(7):707-9. Epub 2006 May 2.

PMID:
16650963
7.

Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.

Sicking I, Rommens K, Battista MJ, Böhm D, Gebhard S, Lebrecht A, Cotarelo C, Hoffmann G, Hengstler JG, Schmidt M.

BMC Cancer. 2014 Dec 15;14:952. doi: 10.1186/1471-2407-14-952.

8.

Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.

Zhao P, Lu Y, Jiang X, Li X.

Cancer Sci. 2011 May;102(5):1107-11. doi: 10.1111/j.1349-7006.2011.01894.x. Epub 2011 Feb 28.

9.

Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?

Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F.

BMC Cancer. 2011 Jul 15;11:299. doi: 10.1186/1471-2407-11-299.

10.

Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.

Hartkopf AD, Taran FA, Wallwiener M, Hahn M, Becker S, Solomayer EF, Brucker SY, Fehm TN, Wallwiener D.

Eur J Cancer. 2014 Oct;50(15):2550-9. doi: 10.1016/j.ejca.2014.06.025. Epub 2014 Aug 2.

PMID:
25096167
11.

Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.

Synnestvedt M, Borgen E, Schlichting E, Schirmer CB, Renolen A, Giercksky KE, Nesland JM, Naume B.

Breast Cancer Res Treat. 2013 Apr;138(2):485-97. doi: 10.1007/s10549-013-2439-8. Epub 2013 Mar 3.

PMID:
23456230
12.

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.

Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.

PMID:
23749689
13.

The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast.

Barısık NO, Keser SH, Gul AE, Sensu S, Kandemir NO, Kucuk HF, Gumus M, Karadayı N.

Med Oncol. 2011 Sep;28(3):703-8. doi: 10.1007/s12032-010-9503-6. Epub 2010 Mar 31.

PMID:
20354817
14.

Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment.

Stefanovic S, Diel I, Sinn P, Englert S, Hennigs A, Mayer C, Schott S, Wallwiener M, Blumenstein M, Golatta M, Heil J, Rom J, Sohn C, Schneeweiss A, Schuetz F, Domschke C.

Ann Surg Oncol. 2016 Mar;23(3):757-66. doi: 10.1245/s10434-015-4895-3. Epub 2015 Oct 14.

PMID:
26467455
15.

COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin.

Holmes MD, Chen WY, Schnitt SJ, Collins L, Colditz GA, Hankinson SE, Tamimi RM.

Breast Cancer Res Treat. 2011 Nov;130(2):657-62. doi: 10.1007/s10549-011-1651-7. Epub 2011 Jul 5.

16.

Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.

Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K.

Clin Cancer Res. 2003 Nov 1;9(14):5313-7.

17.

[Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer].

Zhang B, Liu YX, Cao WF, Cao XC, Ning LS, Hao XS.

Zhonghua Bing Li Xue Za Zhi. 2008 Jul;37(7):471-6. Chinese.

PMID:
19035119
18.

Calpain system protein expression in basal-like and triple-negative invasive breast cancer.

Storr SJ, Lee KW, Woolston CM, Safuan S, Green AR, Macmillan RD, Benhasouna A, Parr T, Ellis IO, Martin SG.

Ann Oncol. 2012 Sep;23(9):2289-96. doi: 10.1093/annonc/mds176. Epub 2012 Jun 27.

19.

Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.

Wernicke AG, Varma S, Greenwood EA, Christos PJ, Chao KS, Liu H, Bander NH, Shin SJ.

APMIS. 2014 Jun;122(6):482-9. doi: 10.1111/apm.12195. Epub 2013 Dec 5.

PMID:
24304465
20.

Supplemental Content

Support Center